Navigation Links
Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/28/2013

r which proceeds are to be used for general corporate and working capital purposes including the funding of clinical trials
  • Initiated the TAKSTA Phase 2 clinical trial in patients with prosthetic joint infections (PJIs)
  • Initiated the oral solithromycin Phase 3 clinical trial in patients with community-acquired bacterial pneumonia
  • Clinical program updateThe company is primarily focused on the development of its two lead clinical-stage antibiotic candidates, the fluoroketolide, solithromycin, in clinical development for CABP and uncomplicated gonococcal infections and TAKSTA, the oral antibiotic being developed for prosthetic joint infections.  The company expects the following events to occur during 2013:

    Solithromycin

  • 1H13: End of Phase 2 meeting with the FDA
  • 2H13: Initiation of the IV-to-oral Phase 3 clinical trial in CABP, subject to available resources
  • TAKSTA

  • 4Q13: Top-line results of the Phase 2 trial in PJI patients
  • Financial GuidanceCempra expects its research and development expense to increase due to the initiation of the solithromycin Phase 3 and the TAKSTA Phase 2 clinical trials during the fourth quarter of 2012.  The company's cash and equivalents are expected to be sufficient to fund current operations into 2015.  This projection does not include initiation of the planned IV-to-oral solithromycin Phase 3 trial.

    Conference Call and WebcastThe conference call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers. Please specify to the operator that you would like to join the "Cempra, Inc., Full year 2012 Financial Results Call, conference ID#: 12497222." The conference call will be webcast live under the investor relations section of Cempra's website at www.cempra.com, and will be archived there for 30 days following the call. Please visit Cempra's website several
    '/>"/>

    SOURCE Cempra, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. United States Patent and Trademark Office to Require Signed NDA Affects Many Reports Wysebridge
    2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
    3. Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
    4. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
    5. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
    6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    7. Neuland Labs Reports Third Quarter Fiscal Year 2013 Financial Results
    8. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
    9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
    10. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
    11. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
    (Date:8/18/2014)... (Aug. 18, 2014) -- A new therapy developed ... (USF) Morsani College of Medicine and Columbia University ... complications of interventional cardiovascular disease treatment. , ... the novel molecular therapy could selectively inhibit blood ... a medical procedure using a balloon catheter to ...
    (Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
    (Date:8/18/2014)... NYElectronic devices with unprecedented efficiency and data ... that use built-in electric polarizations to read ... inside most popular data-driven technology. But ferroelectrics ... blocks, including a curious habit of "forgetting" ... the U.S. Department of Energy,s Brookhaven National ...
    Breaking Biology Technology:Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
    ... ROCKVILLE, Md., Nov. 4 Novavax, Inc. (Nasdaq:,NVAX) today ... financial,results in a press release to be issued after ... will hold an investor conference call to,discuss its financial ... The call will be hosted by Novavax President and ...
    ... Lead Cancer Stem Cell Product Candidate Enters Clinical ... OncoMed Pharmaceuticals, a,clinical-stage company developing novel antibody therapeutics ... completion of the final,tranche of its Series B ... total Series B financing to $154 million. New ...
    ... at Berlin conference, RALEIGH, N.C., Nov. 4 ... it will present during the,Partnerships in Clinical Trials ... PRA,s Christian Tucat, Senior Vice President of Business,Development ... evolution of CRO,partnerships?" at 4PM on Wednesday, 5 ...
    Cached Biology Technology:Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call 2OncoMed Pharmaceuticals Completes Series B Financing 2OncoMed Pharmaceuticals Completes Series B Financing 3PRA International Addresses Sponsor-CRO Partnering Strategies at European Partnerships in Clinical Trials Congress 2
    (Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
    (Date:8/20/2014)... to about 4,000 members, it triggers an important first ... special type of comb used for rearing male reproductive, ... of Neurobiology and Behaviour at Cornell University, led by ... honeybee colonies. The results are published in Springer,s journal ... , Reproduction isn,t always a honeybee colony,s top priority. ...
    (Date:8/20/2014)... ROBERTS, Washington , August 20, 2014 ... Security Concerns in the Payment Industry?   ... sectors including biometrics, issues commentary from analysts and experts on ... , Managing Partner at Thrive Analytics, Isabelle Moeller ... of NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ), a biometric ...
    Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
    ... Vision Australia (BVA) today unveils their wide-view neurostimulator concept ... Australia,s first recipient of the technology. The ... University of New South Wales and unveiled today at ... Melbourne, will deliver improved quality of life for patients ...
    ... helping fight a multi-front war on cancer may do the ... Cancer and cardiovascular disease, both among top U.S. killers, ... as a treatment could become additional common ground, said Dr. ... think hsp90 inhibitors may be some of the best anti-inflammatory ...
    ... March 30, 2010 Two new tuberculosis studies by ... bad news about the bacterium that infects nearly a ... kills nearly 2 million people each year. ... shows promise at overcoming some drug-resistant tuberculosis, at least ...
    Cached Biology News:Bionic Vision Australia puts bionic eye in sight 2New cancer therapy may fight cardiovascular disease 2UT Southwestern researchers find clues to TB drug resistance 2UT Southwestern researchers find clues to TB drug resistance 3
    ... Our fastest automated perfusion system. ... in perfusion, physiology, biophysics, electrochemistry, or ... reproducibility with 1.5-4 millisecond accuracy ... Microprocessor-based for accuracy and flexibility ...
    Recombinant Human PTP1B (aa 2-321), CF...
    ... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... supernates and serum. Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
    FGF Receptor 1 Antibody...
    Biology Products: